<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541397</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-11-0119</org_study_id>
    <nct_id>NCT01541397</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy</brief_title>
  <official_title>Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to compare the bone mineral density in adults with HPA on KUVAN™ therapy to
      those not on therapy. The investigators hypothesize that after one year of KUVAN™ therapy,
      there will be an improvement in their bone mineral density.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperphenylalaninemia (HPA) is a rare metabolic disorder caused by a deficiency of the enzyme
      phenylalanine hydroxylase (PAH) (NIH, October 16-18, 2000). Elevated plasma levels of
      phenylalanine (phe) cause mental retardation, microcephaly, delayed speech, seizures, eczema,
      and behavior abnormalities. Adequate control of the plasma levels of phe by a phe-restricted
      diet can prevent the developmental and behavioral problems.

      The foundation of this diet is a phe-free metabolic medical product/formula made from free
      amino acids. Based on longitudinal studies, it has been reported that the most benefit is
      attained by individuals who maintain a phe-restricted diet throughout life. On December 13,
      2007, KUVAN™ (sapropterin dihydrochloride) was approved by the FDA for the indication of
      reducing blood phe levels in patients with HPA due to BH4 responsive PKU, in conjunction with
      a phe restricted diet (BioMarin Pharmaceutical Inc., Investigator's Brochure March 25, 2008).
      Studies were performed to determine a definition of response to KUVAN™. In a phase 2 clinical
      trial in 2007, Burton, et. al. defined a Kuvan™ responder as having a 30% or greater
      improvement in blood phenylalanine levels compared to baseline after 8 days of drug therapy.

      Kuvan™ has been shown to improve phenylalanine tolerance in some individuals with HPA. This
      drug enables these individuals to consume more protein from natural sources. However, there
      have been no research studies assessing the effects of KUVAN™ along with liberalization of
      the diet on bone mineral density.

      The investigators propose a prospective study to compare the bone mineral density in adults
      with HPA on KUVAN™ therapy to those not on therapy. The investigators hypothesize that after
      one year of KUVAN™ therapy, there will be an improvement in their bone mineral density.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>1 year after initiation of Kuvan therapy</time_frame>
    <description>A DXA scan will be conducted one year after Kuvan therapy is initiated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Amino Acid Profile</measure>
    <time_frame>every three months up to 1 year</time_frame>
    <description>Evaluation of levels of plasma amino acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diet Analysis</measure>
    <time_frame>every 3 months up to 1 year</time_frame>
    <description>Subjects will provide a 3 day diet record for every plasma amino acid evaluation. Diets will be analyzed to determine phenylalanine, protein, calories, fat, vitamins and minerals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Phenylalanine Levels</measure>
    <time_frame>weekly for 6 weeks, then at least every three months up to 1 year</time_frame>
    <description>Plasma phenylalanine levels will be monitored to determine effectiveness of Kuvan therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Hyperphenylalaninemia</condition>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>Non-Kuvan treated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kuvan treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sapropterin</intervention_name>
    <description>20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
    <arm_group_label>Kuvan treated</arm_group_label>
    <other_name>Kuvan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hyperphenylalaninemia at birth

          -  Age between 18 and 50 years

          -  Participated in study HSC-MS-110-0262

        Exclusion Criteria:

          -  Peri-menopausal and menopausal women will be excluded because this is a time of
             increased bone loss related to hormonal mediated factors.

          -  Patients taking bisphosphonates because it alters bone density. Therefore, bone
             mineral density would reflect the biphosphonate intervention rather than their true
             status.

          -  Pregnant women due to the hazard of radiation exposure during a DXA scan. In addition
             women who have been pregnant or who have breastfed within one year of study enrollment
             will be excluded because these are periods of rapid bone loss which would not reflect
             the entity under study but would serve to confound the data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather W Saavedra, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <results_first_submitted>June 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2015</results_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Heather Saavedra</investigator_full_name>
    <investigator_title>Nutritionist; Department of Pediatrics Division of Genetics</investigator_title>
  </responsible_party>
  <keyword>Hyperphenylalaninemia</keyword>
  <keyword>Phenylketonuria</keyword>
  <keyword>Adults</keyword>
  <keyword>Bone Mineral Density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
        </group>
        <group group_id="P2">
          <title>Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study ended prior to data collection</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
        </group>
        <group group_id="B2">
          <title>Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density</title>
        <description>A DXA scan will be conducted one year after Kuvan therapy is initiated.</description>
        <time_frame>1 year after initiation of Kuvan therapy</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>A DXA scan will be conducted one year after Kuvan therapy is initiated.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Amino Acid Profile</title>
        <description>Evaluation of levels of plasma amino acids.</description>
        <time_frame>every three months up to 1 year</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Amino Acid Profile</title>
          <description>Evaluation of levels of plasma amino acids.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diet Analysis</title>
        <description>Subjects will provide a 3 day diet record for every plasma amino acid evaluation. Diets will be analyzed to determine phenylalanine, protein, calories, fat, vitamins and minerals.</description>
        <time_frame>every 3 months up to 1 year</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Diet Analysis</title>
          <description>Subjects will provide a 3 day diet record for every plasma amino acid evaluation. Diets will be analyzed to determine phenylalanine, protein, calories, fat, vitamins and minerals.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Phenylalanine Levels</title>
        <description>Plasma phenylalanine levels will be monitored to determine effectiveness of Kuvan therapy.</description>
        <time_frame>weekly for 6 weeks, then at least every three months up to 1 year</time_frame>
        <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
          </group>
          <group group_id="O2">
            <title>Kuvan Treated</title>
            <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Phenylalanine Levels</title>
          <description>Plasma phenylalanine levels will be monitored to determine effectiveness of Kuvan therapy.</description>
          <population>Zero participants were analyzed because the study was ended early (due to an insufficient number of enrolled participants).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non-Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.</description>
        </group>
        <group group_id="E2">
          <title>Kuvan Treated</title>
          <description>Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
Sapropterin: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Saavedra</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-500-7098</phone>
      <email>Heather.Saavedra@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

